Cargando…
Correction: Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance
Autores principales: | Lu, Yonggang, Shen, Haoming, Huang, Wenjie, He, Sha, Chen, Jianlin, Zhang, Di, Shen, Yongqi, Sun, Yifan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861155/ https://www.ncbi.nlm.nih.gov/pubmed/35190539 http://dx.doi.org/10.1038/s41420-022-00836-6 |
Ejemplares similares
-
Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance
por: Lu, Yonggang, et al.
Publicado: (2021) -
Genome-scale CRISPR-Cas9 knockout screening in nasopharyngeal carcinoma for radiosensitive and radioresistant genes
por: Zhou, Ziyan, et al.
Publicado: (2023) -
JACKS: joint analysis of CRISPR/Cas9 knockout screens
por: Allen, Felicity, et al.
Publicado: (2019) -
Genome-scale CRISPR-Cas9 knockout screening in gastrointestinal stromal tumor with Imatinib resistance
por: Cao, Jie, et al.
Publicado: (2018) -
Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma
por: Huang, Shanzhou, et al.
Publicado: (2022)